KI3L2_HUMAN
ID KI3L2_HUMAN Reviewed; 455 AA.
AC P43630; Q13238; Q14947; Q14948; Q92684; Q95366; Q95367; Q95368;
DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1995, sequence version 1.
DT 03-AUG-2022, entry version 198.
DE RecName: Full=Killer cell immunoglobulin-like receptor 3DL2 {ECO:0000305};
DE AltName: Full=CD158 antigen-like family member K;
DE AltName: Full=Natural killer-associated transcript 4;
DE Short=NKAT-4;
DE AltName: Full=p70 natural killer cell receptor clone CL-5;
DE Short=p70 NK receptor CL-5;
DE AltName: CD_antigen=CD158k;
DE Flags: Precursor;
GN Name=KIR3DL2 {ECO:0000303|PubMed:24018270, ECO:0000312|HGNC:HGNC:6339};
GN Synonyms=CD158K, NKAT4;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC TISSUE=Natural killer cell;
RX PubMed=7716543; DOI=10.1126/science.7716543;
RA Colonna M., Samaridis J.;
RT "Cloning of immunoglobulin-superfamily members associated with HLA-C and
RT HLA-B recognition by human natural killer cells.";
RL Science 268:405-408(1995).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC TISSUE=Peripheral blood lymphocyte;
RX PubMed=8777725; DOI=10.1016/1074-7613(95)90069-1;
RA Wagtmann N., Rajagopalan S., Winter C.C., Peruzzi M., Long E.O.;
RT "Killer cell inhibitory receptors specific for HLA-C and HLA-B identified
RT by direct binding and by functional transfer.";
RL Immunity 3:801-809(1995).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS ALA-40;
RP VAL-113; ASP-158 AND HIS-166.
RC TISSUE=Lymphoid tissue;
RX PubMed=8760804; DOI=10.1084/jem.184.2.505;
RA Pende D., Biassoni R., Cantoni C., Verdiani S., Falco M., di Donato C.,
RA Accame L., Bottino C., Moretta A., Moretta L.;
RT "The natural killer cell receptor specific for HLA-A allotypes: a novel
RT member of the p58/p70 family of inhibitory receptors that is characterized
RT by three immunoglobulin-like domains and is expressed as a 140-kD
RT disulphide-linked dimer.";
RL J. Exp. Med. 184:505-518(1996).
RN [4]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=8662091; DOI=10.1007/bf02602590;
RA Doehring C., Samaridis J., Colonna M.;
RT "Alternatively spliced forms of human killer inhibitory receptors.";
RL Immunogenetics 44:227-230(1996).
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-158.
RA Yawata N., Yawata M., Parham P.;
RT "Variants of KIR identified in Japanese donors.";
RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN [6]
RP FUNCTION, SUBUNIT, AND INTERACTION WITH HLA-F.
RX PubMed=24018270; DOI=10.4049/jimmunol.1300081;
RA Goodridge J.P., Burian A., Lee N., Geraghty D.E.;
RT "HLA-F and MHC class I open conformers are ligands for NK cell Ig-like
RT receptors.";
RL J. Immunol. 191:3553-3562(2013).
RN [7]
RP FUNCTION, AND TISSUE SPECIFICITY.
RX PubMed=26928464; DOI=10.1038/nm.4052;
RA Song S., Miranda C.J., Braun L., Meyer K., Frakes A.E., Ferraiuolo L.,
RA Likhite S., Bevan A.K., Foust K.D., McConnell M.J., Walker C.M.,
RA Kaspar B.K.;
RT "Major histocompatibility complex class I molecules protect motor neurons
RT from astrocyte-induced toxicity in amyotrophic lateral sclerosis.";
RL Nat. Med. 22:397-403(2016).
RN [8]
RP FUNCTION, SUBUNIT, AND INTERACTION WITH HLA-F.
RX PubMed=28636952; DOI=10.1016/j.immuni.2017.06.002;
RA Dulberger C.L., McMurtrey C.P., Holzemer A., Neu K.E., Liu V.,
RA Steinbach A.M., Garcia-Beltran W.F., Sulak M., Jabri B., Lynch V.J.,
RA Altfeld M., Hildebrand W.H., Adams E.J.;
RT "Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through
RT Interactions with NK Cell Receptors.";
RL Immunity 46:1018-1029(2017).
RN [9]
RP VARIANTS ALA-40; VAL-113; ASP-158; HIS-166; PRO-228 AND THR-252.
RX PubMed=9430221; DOI=10.1016/s1074-7613(00)80394-5;
RA Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K.,
RA Corliss B., Tyan D., Lanier L.L., Parham P.;
RT "Human diversity in killer cell inhibitory receptor genes.";
RL Immunity 7:753-763(1997).
CC -!- FUNCTION: Receptor on natural killer (NK) cells and T cells for MHC
CC class I molecules (PubMed:24018270, PubMed:28636952). Upon binding of
CC peptide-free HLA-F open conformer, negatively regulates NK and T cell
CC effector functions (PubMed:24018270). Acts as a receptor on astrocytes
CC for HLA-F. Through interaction with HLA-F, may protect motor neurons
CC from astrocyte-induced toxicity (PubMed:26928464).
CC {ECO:0000269|PubMed:24018270, ECO:0000269|PubMed:26928464,
CC ECO:0000269|PubMed:28636952}.
CC -!- SUBUNIT: Interacts with peptide-free HLA-F open conformer.
CC {ECO:0000269|PubMed:24018270, ECO:0000269|PubMed:28636952}.
CC -!- INTERACTION:
CC P43630; P30511: HLA-F; NbExp=6; IntAct=EBI-6165894, EBI-2811134;
CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC protein.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=P43630-1; Sequence=Displayed;
CC Name=2;
CC IsoId=P43630-2; Sequence=VSP_047374;
CC -!- TISSUE SPECIFICITY: Expressed in astrocytes.
CC {ECO:0000269|PubMed:26928464}.
CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; L41270; AAA69871.1; -; mRNA.
DR EMBL; U30272; AAB52520.1; -; mRNA.
DR EMBL; X93595; CAA63791.1; -; mRNA.
DR EMBL; X93596; CAA63792.1; -; mRNA.
DR EMBL; X94373; CAA64150.1; -; mRNA.
DR EMBL; X94374; CAA64151.1; -; mRNA.
DR EMBL; L76665; AAB36593.1; -; mRNA.
DR EMBL; L76666; AAB36594.1; -; mRNA.
DR EMBL; AY789067; AAX23112.1; -; mRNA.
DR CCDS; CCDS12906.1; -. [P43630-1]
DR CCDS; CCDS58677.1; -. [P43630-2]
DR RefSeq; NP_001229796.1; NM_001242867.1. [P43630-2]
DR RefSeq; NP_006728.2; NM_006737.3. [P43630-1]
DR AlphaFoldDB; P43630; -.
DR SMR; P43630; -.
DR BioGRID; 110013; 37.
DR ELM; P43630; -.
DR IntAct; P43630; 24.
DR STRING; 9606.ENSP00000325525; -.
DR ChEMBL; CHEMBL4630895; -.
DR GlyGen; P43630; 4 sites.
DR iPTMnet; P43630; -.
DR PhosphoSitePlus; P43630; -.
DR SwissPalm; P43630; -.
DR BioMuta; KIR3DL2; -.
DR DMDM; 1171729; -.
DR MassIVE; P43630; -.
DR PaxDb; P43630; -.
DR PeptideAtlas; P43630; -.
DR PRIDE; P43630; -.
DR ProteomicsDB; 55644; -. [P43630-1]
DR ABCD; P43630; 12 sequenced antibodies.
DR Antibodypedia; 52684; 131 antibodies from 19 providers.
DR DNASU; 3812; -.
DR Ensembl; ENST00000270442.5; ENSP00000270442.5; ENSG00000240403.5. [P43630-2]
DR Ensembl; ENST00000326321.7; ENSP00000325525.3; ENSG00000240403.5. [P43630-1]
DR Ensembl; ENST00000611608.4; ENSP00000479903.1; ENSG00000278809.4. [P43630-1]
DR Ensembl; ENST00000611628.4; ENSP00000481662.1; ENSG00000278474.4.
DR Ensembl; ENST00000611859.1; ENSP00000480578.1; ENSG00000277181.4. [P43630-2]
DR Ensembl; ENST00000612138.1; ENSP00000482589.1; ENSG00000274722.4. [P43630-2]
DR Ensembl; ENST00000613610.4; ENSP00000482301.1; ENSG00000278442.4.
DR Ensembl; ENST00000613612.4; ENSP00000482565.1; ENSG00000275566.4.
DR Ensembl; ENST00000614753.4; ENSP00000479299.1; ENSG00000276357.4.
DR Ensembl; ENST00000617354.4; ENSP00000482110.1; ENSG00000274722.4. [P43630-1]
DR Ensembl; ENST00000617481.1; ENSP00000481306.1; ENSG00000275083.4. [P43630-2]
DR Ensembl; ENST00000617666.4; ENSP00000481209.1; ENSG00000278361.4.
DR Ensembl; ENST00000617957.4; ENSP00000481579.1; ENSG00000275083.4. [P43630-1]
DR Ensembl; ENST00000618273.1; ENSP00000481871.1; ENSG00000276739.4. [P43630-2]
DR Ensembl; ENST00000619683.4; ENSP00000478251.1; ENSG00000275626.4.
DR Ensembl; ENST00000620817.4; ENSP00000479772.1; ENSG00000276739.4. [P43630-1]
DR Ensembl; ENST00000621155.4; ENSP00000477519.1; ENSG00000275416.4.
DR Ensembl; ENST00000622024.4; ENSP00000479425.1; ENSG00000276004.4.
DR Ensembl; ENST00000622453.4; ENSP00000477516.1; ENSG00000277181.4. [P43630-1]
DR Ensembl; ENST00000622579.1; ENSP00000482655.1; ENSG00000278809.4. [P43630-2]
DR Ensembl; ENST00000638330.2; ENSP00000492261.2; ENSG00000284381.2. [P43630-1]
DR Ensembl; ENST00000638726.1; ENSP00000492117.1; ENSG00000283951.1. [P43630-2]
DR Ensembl; ENST00000638805.1; ENSP00000492880.1; ENSG00000283975.1. [P43630-2]
DR Ensembl; ENST00000638891.1; ENSP00000491303.1; ENSG00000284063.1. [P43630-1]
DR Ensembl; ENST00000638970.1; ENSP00000491183.1; ENSG00000283975.1. [P43630-1]
DR Ensembl; ENST00000639252.2; ENSP00000491248.2; ENSG00000284381.2. [P43630-2]
DR Ensembl; ENST00000639313.1; ENSP00000491707.1; ENSG00000284063.1. [P43630-2]
DR Ensembl; ENST00000640782.1; ENSP00000491436.1; ENSG00000283951.1. [P43630-1]
DR GeneID; 3812; -.
DR KEGG; hsa:3812; -.
DR MANE-Select; ENST00000326321.7; ENSP00000325525.3; NM_006737.4; NP_006728.2.
DR UCSC; uc002qho.5; human. [P43630-1]
DR CTD; 3812; -.
DR DisGeNET; 3812; -.
DR GeneCards; KIR3DL2; -.
DR HGNC; HGNC:6339; KIR3DL2.
DR HPA; ENSG00000240403; Tissue enhanced (lymphoid).
DR MIM; 604947; gene.
DR neXtProt; NX_P43630; -.
DR OpenTargets; ENSG00000240403; -.
DR PharmGKB; PA30124; -.
DR VEuPathDB; HostDB:ENSG00000240403; -.
DR eggNOG; ENOG502RU21; Eukaryota.
DR GeneTree; ENSGT01000000214458; -.
DR HOGENOM; CLU_021100_2_1_1; -.
DR InParanoid; P43630; -.
DR OMA; GEAREYR; -.
DR PhylomeDB; P43630; -.
DR TreeFam; TF352669; -.
DR PathwayCommons; P43630; -.
DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR SignaLink; P43630; -.
DR BioGRID-ORCS; 3812; 6 hits in 1054 CRISPR screens.
DR GeneWiki; KIR3DL2; -.
DR GenomeRNAi; 3812; -.
DR Pharos; P43630; Tbio.
DR PRO; PR:P43630; -.
DR Proteomes; UP000005640; Chromosome 19.
DR RNAct; P43630; protein.
DR Bgee; ENSG00000240403; Expressed in granulocyte and 36 other tissues.
DR ExpressionAtlas; P43630; baseline and differential.
DR Genevisible; P43630; HS.
DR GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR GO; GO:0023029; F:MHC class Ib protein binding; IDA:UniProtKB.
DR GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR GO; GO:1901215; P:negative regulation of neuron death; IMP:UniProtKB.
DR Gene3D; 2.60.40.10; -; 3.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR003599; Ig_sub.
DR InterPro; IPR013151; Immunoglobulin.
DR Pfam; PF00047; ig; 3.
DR SMART; SM00409; IG; 3.
DR SUPFAM; SSF48726; SSF48726; 3.
PE 1: Evidence at protein level;
KW Alternative splicing; Cell membrane; Disulfide bond; Glycoprotein;
KW Immunoglobulin domain; Membrane; Receptor; Reference proteome; Repeat;
KW Signal; Transmembrane; Transmembrane helix.
FT SIGNAL 1..21
FT /evidence="ECO:0000250"
FT CHAIN 22..455
FT /note="Killer cell immunoglobulin-like receptor 3DL2"
FT /id="PRO_0000015090"
FT TOPO_DOM 22..340
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 341..360
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 361..455
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT DOMAIN 42..102
FT /note="Ig-like C2-type 1"
FT DOMAIN 137..202
FT /note="Ig-like C2-type 2"
FT DOMAIN 237..300
FT /note="Ig-like C2-type 3"
FT CARBOHYD 179
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 239
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 273
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 306
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 49..95
FT /evidence="ECO:0000305"
FT DISULFID 144..195
FT /evidence="ECO:0000250|UniProtKB:Q8NHL6"
FT DISULFID 244..293
FT /evidence="ECO:0000250|UniProtKB:Q8NHL6"
FT VAR_SEQ 318..334
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:8760804"
FT /id="VSP_047374"
FT VARIANT 40
FT /note="P -> A"
FT /evidence="ECO:0000269|PubMed:8760804,
FT ECO:0000269|PubMed:9430221"
FT /id="VAR_010325"
FT VARIANT 113
FT /note="L -> V (in dbSNP:rs3188286)"
FT /evidence="ECO:0000269|PubMed:8760804,
FT ECO:0000269|PubMed:9430221"
FT /id="VAR_010326"
FT VARIANT 158
FT /note="E -> D (in dbSNP:rs633870)"
FT /evidence="ECO:0000269|PubMed:8760804,
FT ECO:0000269|PubMed:9430221, ECO:0000269|Ref.5"
FT /id="VAR_010327"
FT VARIANT 166
FT /note="R -> H (in dbSNP:rs1048271)"
FT /evidence="ECO:0000269|PubMed:8760804,
FT ECO:0000269|PubMed:9430221"
FT /id="VAR_010328"
FT VARIANT 228
FT /note="A -> P (in dbSNP:rs1377032475)"
FT /evidence="ECO:0000269|PubMed:9430221"
FT /id="VAR_010329"
FT VARIANT 252
FT /note="I -> T"
FT /evidence="ECO:0000269|PubMed:9430221"
FT /id="VAR_010330"
FT VARIANT 397
FT /note="T -> M (in dbSNP:rs3745902)"
FT /id="VAR_049992"
FT VARIANT 439
FT /note="K -> Q (in dbSNP:rs3745903)"
FT /id="VAR_049993"
SQ SEQUENCE 455 AA; 50230 MW; DB4BA6BB6B3C2945 CRC64;
MSLTVVSMAC VGFFLLQGAW PLMGGQDKPF LSARPSTVVP RGGHVALQCH YRRGFNNFML
YKEDRSHVPI FHGRIFQESF IMGPVTPAHA GTYRCRGSRP HSLTGWSAPS NPLVIMVTGN
HRKPSLLAHP GPLLKSGETV ILQCWSDVMF EHFFLHREGI SEDPSRLVGQ IHDGVSKANF
SIGPLMPVLA GTYRCYGSVP HSPYQLSAPS DPLDIVITGL YEKPSLSAQP GPTVQAGENV
TLSCSSWSSY DIYHLSREGE AHERRLRAVP KVNRTFQADF PLGPATHGGT YRCFGSFRAL
PCVWSNSSDP LLVSVTGNPS SSWPSPTEPS SKSGICRHLH VLIGTSVVIF LFILLLFFLL
YRWCSNKKNA AVMDQEPAGD RTVNRQDSDE QDPQEVTYAQ LDHCVFIQRK ISRPSQRPKT
PLTDTSVYTE LPNAEPRSKV VSCPRAPQSG LEGVF
